Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst on February 13. Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on the stock and has a $429.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitney Ijem has given his Buy rating due to a combination of factors tied to Alnylam’s execution and growth outlook. He emphasizes that the Amvuttra launch in transthyretin-mediated amyloidosis is significantly outperforming initial expectations, with current sales nearly double what the market anticipated at approval and company guidance implying continued strong top-line expansion into 2026.
Beyond Amvuttra, Ijem highlights substantial long-term optionality from the broader pipeline, particularly Zilebesiran in hypertension, where he projects multibillion-dollar peak sales later in the next decade. He also notes that numerous additional late- and early-stage programs are only partially reflected in his model, and combined with Alnylam’s consistent scientific, clinical, and commercial execution, this underpins his view that the shares remain attractive despite potential near-term volatility and a relatively quiet upcoming news period.
Ijem covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Fractyl Health, Inc., and BioMarin Pharmaceutical. According to TipRanks, Ijem has an average return of 21.2% and a 51.54% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $527.00 price target.